MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly ... The Food and Drug Administration cleared GSK’s shot for adults aged 50 to 59 years who ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Neither of the vaccines, Pfizer Abrysvo made by Pfizer ... have had no serious side effects, the CDC says. FDA approves first ...

The prescribing information for two respiratory syncytial virus (RSV ... (manufactured by Pfizer) and Arexvy (manufactured by GlaxoSmithKline), according to the FDA communication.

Last year, the agency recommended RSV vaccines for people 75 ... acquisition firmly under its belt, Pfizer has solid footing in the hot antibody-drug conjugate (ADC) market, Edward Jones ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré Syndrome, according to experts in the US ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...